Dries Deeren

Sequential serum galactomannan as outcome marker for invasive aspergillosis—An exploratory study from the FungiScope registry

Christina Többen, Oliver A. Cornely, Carolin S. Joisten, Ertan Sal et autres

BACKGROUND: Galactomannan index (GMI) is established as a diagnostic tool for invasive aspergillosis (IA), while its utility in monitoring antifungal treatment (AFT) response and prognostic value remains unclear. This study evaluated the validity of serum GM as a biomarker for AFT monitoring …

de, ar, fr, tr, us, es, be, pe, gb (code pays fourni par la source)

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

Laurie Helen Sehn, Kai Hübel, Stefano Luminari, Christian Wilfried Scholz et autres

ca, de, it, gb, se, gr, au, es, kr, jp, us, fr, be, ch, cz (code pays fourni par la source)

Real‐World Safety Data From the World Apheresis Association Registry for the Spectra Optia Apheresis System

Aaron J. Haubner, Hans Vrielink, Volker Witt, Dries Deeren et autres

In this study we analyzed 12 years of adverse events, (AE) data from the World Apheresis Association, (WAA) Registry specific to the Spectra Optia Apheresis System. We queried WAA Registry data, (2012-2023) on apheresis procedures performed exclusively on the Spectra Optia Apheresis …

de, nl, at, be, hr, cz, no, Afrique du Sud, se, au (code pays fourni par la source)

Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus

Amer Methqal Zeidan, María Diez‐Campelo, Valeria Santini, Rena J. Buckstein et autres

Abstract Background: Luspatercept is an erythroid-maturation agent approved to treat anemia in patients (pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS) who are erythropoiesis-stimulating agent (ESA)–naive or –exposed. Luspatercept improved red blood cell (RBC) transfusion independence (RBC-TI) in pts in the COMMANDS …

us, es, it, ca, fr, se, ch, pl, be, de (code pays fourni par la source)

Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML

Pau Montesinos, James M. Foran, Harry Paul Erba, Eduardo Rodriguez Arboli et autres

PURPOSE Ziftomenib—a potent, highly selective, oral menin inhibitor—was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1 -mutated ( NPM1 -m) and KMT2A -rearranged AML in the KOMET-001 phase I trial. METHODS In the registration-enabling phase II part of …

us, ca, es, fr, de, it (code pays fourni par la source)

Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia

Daniel Aaron Pollyea, Tessa C. C. Kerre, Dries Deeren, Y Beguin et autres

us, be (code pays fourni par la source)

MDS-736: Preliminary Efficacy and Safety Analysis of the MAXILUS Study of Luspatercept (LUSPA) Initiated at the Maximum Approved Dose in Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Amer M. Zeidan, María Díez‐Campelo, Valeria Santini, Rena J. Buckstein et autres

us, es, it, ca, fr, ch, pl, be, de (code pays fourni par la source)

POSTER: MDS-736 Preliminary Efficacy and Safety Analysis of the MAXILUS Study of Luspatercept (LUSPA) Initiated at the Maximum Approved Dose in Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Amer M. Zeidan, María Díez‐Campelo, Valeria Santini, Rena J. Buckstein et autres

us, es, it, ca, fr, ch, pl, be, de (code pays fourni par la source)

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry

Timothy Devos, Dries Deeren, Koen Theunissen, Dominik Selleslag et autres

Background: Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) for treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in patients who fail or are intolerant to a second generation TKI or who carry the T315I mutation.Method: …

be, nl, us (code pays fourni par la source)

Do high-volume centers really save more lives? A call for scientific rigor and transparency. Comment on: Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy

Dries Deeren

Not available.

be (code pays fourni par la source)

The number of apheresis procedures to treat immune-mediated neurological diseases is on the rise

Kaatje Le Poole, Hans Vrielink, Astrid Aandahl, Tanya Nadia Glatt et autres

Apheresis is used for the treatment of many different diseases, especially when conventional therapy lacks efficacy. There are however some diseases in which apheresis is accepted as first line therapy. The aim of this analysis was to investigate the use of apheresis …

nl, no, Afrique du Sud, cz, be, lt, au, at, se, de, tr, gb (code pays fourni par la source)

234 | POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE inMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Laurie Helen Sehn, Kai Hübel, Stefano Luminari, Christian W. Scholz et autres

ca, de, it, gb, se, au, es, kr, jp, us, fr, be, cz (code pays fourni par la source)